메뉴 건너뛰기




Volumn 31, Issue 4, 2009, Pages 816-820

An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus

Author keywords

glyburide; neonatal diabetes mellitus; sulfonylurea

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); GLIBENCLAMIDE; GLUCOSE; INSULIN;

EID: 65549149008     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.003     Document Type: Article
Times cited : (11)

References (15)
  • 1
    • 33746681908 scopus 로고    scopus 로고
    • ATP-sensitive potassium channels-neonatal diabetes mellitus and beyond
    • Sperling M.A. ATP-sensitive potassium channels-neonatal diabetes mellitus and beyond. N Engl J Med. 355 (2006) 507-510
    • (2006) N Engl J Med. , vol.355 , pp. 507-510
    • Sperling, M.A.1
  • 2
    • 23344439106 scopus 로고    scopus 로고
    • Neonatal diabetes mellitus: From understudy to center stage
    • Sperling M.A. Neonatal diabetes mellitus: From understudy to center stage. Curr Opin Pediatr. 17 (2005) 512-518
    • (2005) Curr Opin Pediatr. , vol.17 , pp. 512-518
    • Sperling, M.A.1
  • 3
    • 33846851524 scopus 로고    scopus 로고
    • The genetic basis of neonatal diabetes mellitus
    • Sperling M.A. The genetic basis of neonatal diabetes mellitus. Pediatr Endocrinol Rev. 4 Suppl 1 (2006) 71-75
    • (2006) Pediatr Endocrinol Rev. , vol.4 , Issue.SUPPL. 1 , pp. 71-75
    • Sperling, M.A.1
  • 4
    • 4644260056 scopus 로고    scopus 로고
    • Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy
    • Sagen J.V., Raeder H., Hathout E., et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes. 53 (2004) 2713-2718
    • (2004) Diabetes. , vol.53 , pp. 2713-2718
    • Sagen, J.V.1    Raeder, H.2    Hathout, E.3
  • 5
    • 8744262895 scopus 로고    scopus 로고
    • Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2
    • Zung A., Glaser B., Nimri R., and Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab. 89 (2004) 5504-5507
    • (2004) J Clin Endocrinol Metab. , vol.89 , pp. 5504-5507
    • Zung, A.1    Glaser, B.2    Nimri, R.3    Zadik, Z.4
  • 6
    • 24144467758 scopus 로고    scopus 로고
    • Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy
    • Hattersley A.T., and Ashcroft F.M. Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy. Diabetes. 54 (2005) 2503-2513
    • (2005) Diabetes. , vol.54 , pp. 2503-2513
    • Hattersley, A.T.1    Ashcroft, F.M.2
  • 7
    • 14644408737 scopus 로고    scopus 로고
    • High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation
    • Codner E., Flanagan S., Ellard S., et al. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care. 28 (2005) 758-759
    • (2005) Diabetes Care. , vol.28 , pp. 758-759
    • Codner, E.1    Flanagan, S.2    Ellard, S.3
  • 8
    • 33746686369 scopus 로고    scopus 로고
    • Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
    • the Neonatal Diabetes International Collaborative Group
    • Pearson E.R., Flechtner I., Njølstad P.R., et al., the Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 355 (2006) 467-477
    • (2006) N Engl J Med. , vol.355 , pp. 467-477
    • Pearson, E.R.1    Flechtner, I.2    Njølstad, P.R.3
  • 9
    • 34147167267 scopus 로고    scopus 로고
    • Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers
    • Stanik J., Gasperikova D., Paskova M., et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab. 92 (2007) 1276-1282
    • (2007) J Clin Endocrinol Metab. , vol.92 , pp. 1276-1282
    • Stanik, J.1    Gasperikova, D.2    Paskova, M.3
  • 10
    • 34247562272 scopus 로고    scopus 로고
    • Sulfonylurea treatment in young children with neonatal diabetes: Dealing with hyperglycemia, hypoglycemia, and sick days
    • Codner E., Flanagan S.E., Ugarte F., et al. Sulfonylurea treatment in young children with neonatal diabetes: Dealing with hyperglycemia, hypoglycemia, and sick days. Diabetes Care. 30 (2007) e28-e29
    • (2007) Diabetes Care. , vol.30
    • Codner, E.1    Flanagan, S.E.2    Ugarte, F.3
  • 11
    • 44649180550 scopus 로고    scopus 로고
    • Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide
    • Bremer A.A., Ranadive S., and Lustig R.H. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide. Pediatr Diabetes. 9 (2008) 236-239
    • (2008) Pediatr Diabetes. , vol.9 , pp. 236-239
    • Bremer, A.A.1    Ranadive, S.2    Lustig, R.H.3
  • 12
    • 52649099443 scopus 로고    scopus 로고
    • Diagnosis and treatment of neonatal diabetes: A United States experience
    • the United States Neonatal Diabetes Working Group
    • Støy J., Greeley S.A., Paz V.P., et al., the United States Neonatal Diabetes Working Group. Diagnosis and treatment of neonatal diabetes: A United States experience. Pediatr Diabetes. 9 (2008) 450-459
    • (2008) Pediatr Diabetes. , vol.9 , pp. 450-459
    • Støy, J.1    Greeley, S.A.2    Paz, V.P.3
  • 13
    • 0018356027 scopus 로고
    • Transient neonatal diabetes mellitus. Treatment with chlorpropamide
    • Kuna P., and Addy D.P. Transient neonatal diabetes mellitus. Treatment with chlorpropamide. Am J Dis Child. 133 (1979) 65-66
    • (1979) Am J Dis Child. , vol.133 , pp. 65-66
    • Kuna, P.1    Addy, D.P.2
  • 14
    • 47649125429 scopus 로고    scopus 로고
    • Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: Initial response to oral sulphonylurea therapy
    • Turkkahraman D., Bircan I., Tribble N.D., et al. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: Initial response to oral sulphonylurea therapy. J Pediatr. 153 (2008) 122-126
    • (2008) J Pediatr. , vol.153 , pp. 122-126
    • Turkkahraman, D.1    Bircan, I.2    Tribble, N.D.3
  • 15
    • 23644442552 scopus 로고    scopus 로고
    • ATP-sensitive potassium: Focus on insulin secretion
    • Ashcroft F.M. ATP-sensitive potassium: Focus on insulin secretion. J Clin Invest. 115 (2005) 2047-2058
    • (2005) J Clin Invest. , vol.115 , pp. 2047-2058
    • Ashcroft, F.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.